Company Filing History:
Years Active: 2010-2012
Title: Profile of Inventor Anna C. Maroney
Introduction
Anna C. Maroney, based in Media, Pennsylvania, is a notable inventor recognized for her contributions to the field of pharmaceutical sciences. With an impressive portfolio of three patents, she has focused her research on innovative compounds that target specific cellular mechanisms. Her work primarily centers on developing compounds that can modulate protein tyrosine kinases, specifically c-Met, contributing to advancements in cancer treatment.
Latest Patents
Anna’s latest patents include the invention of triazolopyridazine compounds that are pivotal in modulating c-Met kinase activity. These compounds are designed to inhibit the kinase activity of c-Met in cells, which is crucial for addressing cell proliferative disorders, particularly cancers. The inventions extend to formulations for pharmaceutical compositions that incorporate these compounds, showcasing their potential in developing treatments for serious health conditions stemming from abnormal cell growth.
Career Highlights
Currently, Anna is affiliated with Janssen Pharmaceutica NV, where her innovative work is translated into practical pharmaceutical applications. Throughout her career, she has demonstrated a commitment to advancing medical research, particularly in understanding and targeting cancerous growths through novel chemical compounds.
Collaborations
In her professional journey, Anna has collaborated with esteemed colleagues including Tianbao Lu and Richard Scott Alexander. These partnerships have cultivated a rich environment for innovation, allowing for the exchange of ideas and the advancement of research efforts in their field.
Conclusion
In summary, Anna C. Maroney is a prominent figure in pharmaceutical innovation, with a distinct focus on triazolopyridazine compounds and their therapeutic applications. Her contributions not only reflect her expertise as an inventor but also highlight the collaborative spirit within the research community, ultimately aiming to improve treatment options for patients suffering from cancer and other related disorders.